1402086-20-7 Usage
Uses
Used in Pharmaceutical Industry:
(S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)acrylamide is used as a potential therapeutic agent for the treatment of various diseases, such as cancer and inflammatory conditions, due to its unique chemical structure and potential interactions with biological targets.
Used in Medicinal Chemistry Research:
(S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)acrylamide serves as a promising candidate for further drug development and research, particularly in the field of medicinal chemistry, where its structure and properties can be explored for the design of new drugs targeting specific diseases.
Used in Drug Design and Development:
(S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)acrylamide is utilized in the design and development of new drugs, leveraging its chemical properties to create novel therapeutic agents with improved efficacy and selectivity for various medical conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 1402086-20-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,0,2,0,8 and 6 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1402086-20:
(9*1)+(8*4)+(7*0)+(6*2)+(5*0)+(4*8)+(3*6)+(2*2)+(1*0)=107
107 % 10 = 7
So 1402086-20-7 is a valid CAS Registry Number.
1402086-20-7Relevant articles and documents
Structure-activity study of quinazoline derivatives leading to the discovery of potent EGFR-T790M inhibitors
Zhang, Long,Yang, Yingying,Zhou, Haojie,Zheng, Qingmei,Li, Yuhao,Zheng, Shansong,Zhao, Shuyong,Chen, Dong,Fan, Chuanwen
, p. 445 - 463 (2015/09/01)
We have developed a series of 6, 7-disubstituted-4-(arylamino) quinazoline derivatives that functioned as irreversible EGFR inhibitors, and these compounds exhibited excellent enzyme inhibition potency. As compared with afatinib, some of them showed significantly enhanced activities towards H1975 cells (EGFR-T790M). Furthermore, the optimized compounds 7q and 8f also demonstrated good pharmacokinetic profiles, oral bioavailability as well as excellent in vivo efficacy in H1975 and HCC827 xenografts at a non-toxic dose. Based on the improved safety and efficacy against EGFR-T790M resistance, 7q and 8f are promising candidates for further studies.
